Brief: Lee's Pharmaceutical Says Phase III Trial Of Staccato Loxapine Meets Primary Endpoint

Lees Pharmaceutical Holdings

03/09/2020 11:20

Sept 3 (Reuters) - Lee's Pharmaceutical Holdings Ltd
 0950.HK :
    * PHASE III TRIAL OF STACCATO LOXAPINE MET ITS PRIMARY
ENDPOINT
    * NEW DRUG APPLICATION EXPECTED TO BE SUBMITTED BY END OF
2020
    * UPDATES ON TRIAL OF STACCATO LOXAPINE FOR TREATMENT OF
AGITATION
ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS

Source text for Eikon:  ID:nHKS6cgvD5 
Further company coverage:  0950.HK 

 ((Reuters.Briefs@thomsonreuters.com;))